PMID- 35104174
OWN - NLM
STAT- MEDLINE
DCOM- 20220420
LR  - 20230202
IS  - 1551-4005 (Electronic)
IS  - 1538-4101 (Print)
IS  - 1551-4005 (Linking)
VI  - 21
IP  - 9
DP  - 2022 May
TI  - Knockdown of RNF183 suppressed proliferation of lung adenocarcinoma cells via 
      inactivating the STAT3 signaling pathway.
PG  - 948-960
LID - 10.1080/15384101.2022.2035617 [doi]
AB  - Proteins of the RNF183 (RING finger 183) family proteins have been reported to be 
      of great importance in tumor the initiation and progression. However, the 
      biological role and regulatory mechanism of RNF183 in non small cell lung cancer 
      (NSCLC) development and progression are poorly defined. Hence, lung 
      adenocarcinoma (LUAD) cell proliferation, cell apoptosis and cell cycle were 
      measured using Cell Counting Kit-8 and flow cytometry analysis, respectively. The 
      correlation between RNF183 and SHP2 (Src homology-2 domain-containing protein 
      tyrosine phosphatase) was measured using coimmunoprecipitation and ubiquitination 
      analysis in vitro. Tumor growth of NSCLC cells in vivo was measured using the 
      nude mouse xenograft model. In this study, we verify that elevated RNF183 
      expression in tumor tissues of LUAD, origin from the TCGA, GEPIA, TIMER, and 
      UALCAN database. RNF183 regulates apoptosis and cell cycle in vitro and tumor 
      growth in vivo by activating the STAT3 pathway through ubiquitination of SHP2, a 
      negative feedback regulator of the STAT3 pathway. Taken together, our results 
      demonstrate that RNF183 regulates proliferation, apoptosis, and cell cycle in 
      LUAD cells via modulation of SHP2/STAT3 signaling, suggesting the potential for 
      targeting the RNF183-SHP2/STAT3 pathway for use in LUAD treatment.
FAU - Ye, Guangbin
AU  - Ye G
AD  - Medical College of Guangxi University, Nanning, Guangxi, PR China.
AD  - School of Basic Medical Sciences, Youjiang Medical University for Nationalities, 
      Baise, Guangxi, PR China.
FAU - Luo, Hongcheng
AU  - Luo H
AD  - Medical College of Guangxi University, Nanning, Guangxi, PR China.
FAU - Zhang, Tingting
AU  - Zhang T
AD  - Medical College of Guangxi University, Nanning, Guangxi, PR China.
FAU - Lan, Tianshu
AU  - Lan T
AD  - Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province 
      University, Xiamen Medical College, Xiamen, Fujian, PR China.
FAU - Ling, Bo
AU  - Ling B
AD  - School of Pharmacy, Youjiang Medical University for Nationalities, Baise, 
      Guangxi, PR China.
FAU - Qi, Zhongquan
AU  - Qi Z
AD  - Medical College of Guangxi University, Nanning, Guangxi, PR China.
AD  - Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province 
      University, Xiamen Medical College, Xiamen, Fujian, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220201
PL  - United States
TA  - Cell Cycle
JT  - Cell cycle (Georgetown, Tex.)
JID - 101137841
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (STAT3 protein, human)
RN  - EC 2.3.2.27 (RNF183 protein, human)
RN  - EC 2.3.2.27 (RNF183 protein, mouse)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
SB  - IM
MH  - *Adenocarcinoma of Lung/genetics/pathology
MH  - Animals
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - Cell Proliferation/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - *Lung Neoplasms/genetics/pathology
MH  - Mice
MH  - STAT3 Transcription Factor/genetics/metabolism
MH  - Signal Transduction
MH  - Ubiquitin-Protein Ligases/genetics/metabolism
PMC - PMC9037501
OTO - NOTNLM
OT  - Lung adenocarcinoma
OT  - RNF183
OT  - STAT3
OT  - proliferation
OT  - ubiquitination
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/02/02 06:00
MHDA- 2022/04/21 06:00
PMCR- 2023/02/01
CRDT- 2022/02/01 17:09
PHST- 2022/02/02 06:00 [pubmed]
PHST- 2022/04/21 06:00 [medline]
PHST- 2022/02/01 17:09 [entrez]
PHST- 2023/02/01 00:00 [pmc-release]
AID - 2035617 [pii]
AID - 10.1080/15384101.2022.2035617 [doi]
PST - ppublish
SO  - Cell Cycle. 2022 May;21(9):948-960. doi: 10.1080/15384101.2022.2035617. Epub 2022 
      Feb 1.